Red yeast rice (RYR) is contained in dietary supplements that are often used by patients with high cholesterol, and it is often proposed as an alternative therapy in those who experience side effects from statins. A new study found that it is not a good choice for statin-intolerant patients: RYR was linked with muscle and liver injury, which can also occur with statin use.
Red yeast rice (RYR) is contained in dietary supplements that are often used by patients with high cholesterol, and it is often proposed as an alternative therapy in those who experience side effects from statins. A new study found that it is not a good choice for statin-intolerant patients: RYR was linked with muscle and liver injury, which can also occur with statin use.
The beneficial effects of RYR are ascribed to monacolins, which are chemically related to statins.
The study’s authors note that statins are prescribed under medical control, and blood tests are periodically performed so that statin use can be stopped as soon as abnormal results are identified. On the contrary, RYR is used as self-prescription, without medical advice and monitoring, so patients risk experiencing toxic effects that may go unnoticed.
“The proportion of serious reports (27%), the relatively rapid time to onset and the lack of concomitant drugs and/or predisposing medications in several cases warrants regulatory consideration and call for: 1) continuous monitoring of “natural” dietary supplements safety through spontaneous reports; 2) appropriate information to clinicians and consumers, who should timely submit suspect reports to regulatory Agencies,” wrote the authors of the British Journal of Clinical Pharmacology study.
Additional Information:
Link to study: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13171/abstract
About Journal
The British Journal of Clinical Pharmacology has the primary goal of publishing high quality research papers on all aspects of drug action in humans. The journal has a wide readership, bridging the medical profession, clinical research and the pharmaceutical industry, and is published monthly. It is owned by the British Pharmacological Society and published by Wiley. The journal’s current Impact Factor is 3.83 (Thomson Reuters Science Citation Index).
Penny Smith-
+44 (0)1243 770171
sciencenewsroom@wiley.com